Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nu-Mega Ingredients is a global leader in the supply of microencapsulated Omega-3 and Omega-6 oils, specializing in docosahexaenoic acid (DHA) for the infant formula and functional food markets. The company utilizes its proprietary Driphorm microencapsulation technology to convert high-quality oils into stable, free-flowing powders that maintain nutritional integrity and sensory neutrality. As a subsidiary of the ASX-listed Clover Corporation, Nu-Mega provides essential lipid ingredients derived from both tuna oil and sustainable algal sources. Their products are designed to support brain and eye development in infants and provide cognitive and cardiovascular benefits in adult nutrition. The company operates advanced manufacturing facilities and maintains a strong focus on research and development to enhance the bioavailability of bioactive lipids.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nu-Mega Ingredients.